Volume 137, Issue 29 e202507388
Forschungsartikel

Ultrasound-Responsive Lipid Nanosonosensitizers with Size Reduction and NO Release: Synergistic Sonodynamic-Chemo-Immunotherapy for Pancreatic Tumors

Leyi Fang

Leyi Fang

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

These authors contributed equally to this work.

Search for more papers by this author
Wenhui Zeng

Wenhui Zeng

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

These authors contributed equally to this work.

Search for more papers by this author
Yili Liu

Yili Liu

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

These authors contributed equally to this work.

Search for more papers by this author
Yinxing Miao

Yinxing Miao

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

Search for more papers by this author
Chunmei Lu

Chunmei Lu

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

Search for more papers by this author
Zhonghan Xu

Zhonghan Xu

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

Search for more papers by this author
Sensen Zhou

Sensen Zhou

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

Search for more papers by this author
Qi Xue

Qi Xue

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

Search for more papers by this author
Yitong Xu

Yitong Xu

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

Search for more papers by this author
Prof. Xiqun Jiang

Prof. Xiqun Jiang

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

Search for more papers by this author
Prof. Jingjuan Xu

Prof. Jingjuan Xu

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

Search for more papers by this author
Prof. Yan Zhang

Corresponding Author

Prof. Yan Zhang

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

E-mail: [email protected]; [email protected]

Search for more papers by this author
Prof. Deju Ye

Corresponding Author

Prof. Deju Ye

State Key Laboratory of Analytical Chemistry for Life Science, Chemistry and Biomedicine Innovation Center (ChemBIC), School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023 China

E-mail: [email protected]; [email protected]

Search for more papers by this author
First published: 13 May 2025

Abstract

Pancreatic cancer (PC) remains difficult to treat due to its dense extracellular matrix (ECM), immunosuppressive tumor microenvironment (TME), and deep-seated anatomy. To address these challenges, we developed IR&ZnPc@LNP-NO, an ultrasound (US)-responsive lipid nanosonosensitizer that synergizes sonodynamic therapy (SDT), chemotherapy, and immunotherapy for orthotopic PC. IR&ZnPc@LNP-NO undergoes three key US-activated responses: 1) size reduction, 2) controlled release of irinotecan (IR) and nitric oxide (NO), and 3) generation of reactive oxygen species (ROS). Under low-dose US, IR&ZnPc@LNP-NO reduces in size (from ∼120  to ∼40 nm), enhancing tumor penetration, and releases NO to remodel the TME by normalizing vasculature and degrading ECM. This enhances nanosonosensitizers accumulation and cytotoxic T cells (CTLs) infiltration. High-dose US irradiation triggers the generation of cytotoxic ROS, which, in combination with IR-mediated chemotherapy, induces immunogenic cell death (ICD) and enhances antitumor immunity. Additionally, combining IR&ZnPc@LNP-NO with PD-L1 antibody (αPD-L1) immunotherapy significantly prolongs survival in orthotopic PC models. The cascade strategy—size reduction, TME remodeling, and multimodal therapy—effectively overcomes stromal and immunosuppressive barriers, offering a robust platform for treating deep-seated PC.

Conflict of Interests

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.